Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
TNGX Stock | USD 2.85 0.25 8.06% |
Slightly above 73% of Tango Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tango Therapeutics suggests that many traders are alarmed. Tango Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tango Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tango |
Dose escalation ongoing in phase 12 trials of lead PRMT5 inhibitors TNG908 and TNG462 additional TNG908 clinical data expected 2024 Dose escalation ongoing in phase 12 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA12-mutant breast and ovarian cancer phase 12 clinical trial initiation expected 1H 2024 Kanishka Pothula, partner at Nexte
Read at finance.yahoo.com
Tango Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Tango Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tango Therapeutics Fundamental Analysis
We analyze Tango Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tango Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tango Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Tango Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Tango Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tango Therapeutics stock to make a market-neutral strategy. Peer analysis of Tango Therapeutics could also be used in its relative valuation, which is a method of valuing Tango Therapeutics by comparing valuation metrics with similar companies.
Peers
Tango Therapeutics Related Equities
PASG | Passage Bio | 2.63 | ||||
BDTX | Black Diamond | 0.79 | ||||
XLO | Xilio Development | 0.96 | ||||
PLRX | Pliant Therapeutics | 2.46 | ||||
CGEM | Cullinan Oncology | 2.56 | ||||
TYRA | Tyra Biosciences | 2.94 | ||||
RVMD | Revolution Medicines | 3.23 | ||||
NRIX | Nurix Therapeutics | 3.40 | ||||
RLAY | Relay Therapeutics | 4.02 | ||||
THRD | Third Harmonic | 4.90 | ||||
STOK | Stoke Therapeutics | 5.08 | ||||
RAPT | RAPT Therapeutics | 5.50 | ||||
EWTX | Edgewise Therapeutics | 5.54 | ||||
MLYS | Mineralys Therapeutics, | 6.02 | ||||
KYMR | Kymera Therapeutics | 6.33 | ||||
FHTX | Foghorn Therapeutics | 6.47 | ||||
CNTB | Connect Biopharma | 6.50 | ||||
RLYB | Rallybio Corp | 6.67 | ||||
GLUE | Monte Rosa | 8.46 | ||||
STTK | Shattuck Labs | 9.77 | ||||
ARVN | Arvinas | 12.42 |
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.